Top Markets
Coin of the day
StageZero Life Sciences Ltd. StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS
株式のランク #36214
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
株価
$0.02770208
最終同期: 2025-03-10
時価総額
$2.92M
変化(1日)
-0.46%
変化(1年)
0.00%
CA
取引 StageZero Life Sciences Ltd. (SZLS)

カテゴリー

StageZero Life Sciences Ltd.(SZLS)のP/B比率
2026 時点のP/B比率 TTM: 0
StageZero Life Sciences Ltd. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
StageZero Life Sciences Ltd. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
4.1431 -
US
2.7156 -
US
- -
CN
24.3791 -
US
27.366 -
US